Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naohuan Dan + idebenone
- Development stage
- Preclinical
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of Naohuan Dan (a traditional Chinese medicine) and idebenone (a synthetic drug) being investigated for the treatment of mild cognitive impairment (MCI) with kidney deficiency and phlegm stasis syndrome. This combination approach represents an integration of traditional Chinese medicine and Western medicine for cognitive disorders. The treatment aims to improve cognitive function, daily living abilities, depression levels, and Traditional Chinese Medicine clinical symptoms in MCI patients.
02
Targets
NADH:ubiquinone oxidoreductase subunit familyMitochondrial respiratory complex I – FMN-associated secondary quinone sitebc1 complex (Cytochrome bc1 complex (plasmodium))NQO1
Beyond the preview
Go deeper on Naohuan Dan + idebenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naohuan Dan + idebenone.